Page 18 - Read Online

Page 14 of 14 Skopis et al. Vessel Plus 2020;4:30 I http://dx.doi.org/10.20517/2574-1209.2020.42

relapsing Wegner’s granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007;25:S23-7.
19. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, et al. A multicenter survey of rituximab therapy for refractory antineutrophil
cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.
20. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J
Am Soc Nephrol 2010;5:1394-400.
21. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, et al. Rituximab for remission induction and maintenance in
refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-8.
22. Baudron-Roubaud C, Pagnoux C, Ruault-Meaux N, Grasland A, Zoulim A, et al. Rituximab maintenance therapy for granulomatosis with
polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-30.
23. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, et al; French Vasculitis Study Group. Rituximab versus azathioprine for
maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
24. Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, et al; French Vasculitis Study Group. Comparison of individually tailored versus
fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled,
phase III trial (MAINRITSAN2). Ann Rheum Dis 2018;77:1143-9.
25. Smith RM, Jayne D, Merkel P. A randomized, controlled trial of Rituximab versus Azathioprine after induction of remission with
Rituximab for patients with ANCA-associated vasculitis and relapsing disease (RITAZAREM) [abstract]. Arthritis Rheumatol 2019;71.
Available from: https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-
remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/. [Last accessed on 28 Sep 2020]
26. Henderson S, Copley S, Pusey C, Ind P, Salama A. Prolonged B cell depletion with Rituximab is effective in treating refractory
pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine(Baltimore) 2014;93;e299.
27. Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 2020;75:124-37.
28. Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan M, et al. Rituximab for treatment of severe renal disease in ANCA associated
vasculitis. J Nephrol 2016;29:195-201.
29. Recillas-Gispert C, Serna-Ojeda JC, Flores-Suárez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis
with polyangiitis (Wegener’s). Graefes Arch Clin Exp Ophthalmol 2015;253:2279-84.
30. Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, et al. Rituximab therapy for refractory orbital inflammation: results of a phase
1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol 2014;132:572-8.
31. Sharma A, Kumar S, Wanchu A, Lal V, Singh R, et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener’s
granulomatosis with rituximab. Clin Rheumatol 2010;29:107-10.
32. Lally L, Lebovics RS, Huang WT, Spiera RF. Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with
polyangiitis (Wegener’s). Arthritis Care Res (Hoboken) 2014;66:1403-9.
33. Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, Tryfon S, Fervenza FC, et al. Diffuse alveolar hemorrhage secondary to antineutrophil
cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol 2016;68:1467-76.
34. Tieu J, Smith R, Basu N, Brogan P, D’Cruz D, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert
consensus guidelines. Rheumatology (Oxford) 2020;59:e24-32.
35. Reitblat T, Wechsler A, Reitblat O. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge
of the treatment. Am J Case Rep 2015;16:211-4.
36. Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic
diseases: a rare event. J Neurovirol 2018;24:323-31.
37. Segelmark L, Flores-suarez LF, Rathmann J, Mohammad A. 271. Severe infections in patients with anca-associated vasculitis treated with
Rituximab. Rheumatology 2019;58:kez062.045.
38. Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-
threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2018;77:1440-7.
39. Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, et al. Rituximab as induction therapy in eosinophilic granulomatosis with
polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract
2017;5:1556-63.
40. van Dam LS, Dirikgil E, Bredewold EW, Ray A, Bakker JA, et al. Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs)
predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant 2020:gfaa066.